Skip to content
Screener

Regeneron Pharmaceuticals REGN Q2 2025 earnings

Reported August 1, 2025 · Before market open

Revenue$3.7BBeat by $387.5M
EPS$12.89Beat by $4.46
Revenue estimate$3.3B
EPS estimate$8.43

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$4.5B
EPS estimate$15.99

Financials

Q2 2025

Income statement

See full
Revenue$3.7B+3.6%
Operating income$1.1B+0.9%
Net income$1.4B-2.8%
EPS (diluted)$12.81+3.2%

Balance sheet

See full
Cash & equivalents$2.0B+4.5%
Total debt$2.7B+0.1%
Total equity$29.9B+6.1%
Total assets$38.2B+5.9%

Cash flow

See full
Operating cash flow$1.1B+223%
CapEx$219.0M+21.3%
Free cash flow$925.4M+433%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$56.39B-50.2%
Enterprise value$57.08B-50.0%
P/E12.6×-13.6×
P/S4×-4.4×

Profitability

See full
Operating margin27%-1.9pp
Net margin31.4%-0.7pp
FCF margin27.1%+2.4pp

Returns & leverage

See full
Return on equity15.3%-1.2pp
Debt / equity0.1×0.0×
Current ratio4.6×-0.8×

FAQ

When did Regeneron Pharmaceuticals report Q2 2025 earnings?
Regeneron Pharmaceuticals (REGN) reported Q2 2025 earnings on August 1, 2025 before market open.
What were Regeneron Pharmaceuticals's Q2 2025 revenue and EPS?
Regeneron Pharmaceuticals reported revenue of $3.7B and eps of $12.89 for Q2 2025.
Did Regeneron Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $3.3B by $387.5M. EPS beat the consensus estimate of $8.43 by $4.46.
How did Regeneron Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.6% from $3.5B a year earlier and eps grew 11.5% from $11.56.
Where can I find Regeneron Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000872589-25-000017) and the 10-Q periodic report (0000872589-25-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.